Speakers

Expand/Collapse

Bernard Allan
Senior Director, Head of Liver Research & Drug Discovery, GI-DDU
Takeda

Day Two

Wednesday, November 3, 2021

11:30 am | Emerging Targets & Treatments for Liver Fibrosis

Bertil Lindmark
Chief Medical Officer
Galecto

Day Two

Wednesday, November 3, 2021

2:00 pm | Panel Discussion: What Does a Creative Clinical Trial Design Look Like & What are the Barriers?

10:30 am | Fibrosis & Cancer: The Intriguing Mechanistic Overlap

Bertram Bleck
Principal Scientist
Takeda

Pre-Conference Seminar Day

5:00 pm | Panel Discussion: Clinical Trial Endpoint Development: Establishing a Pathway for Approving Anti-Stricture Therapies in IBD to Drive Clinical Progress

11:00 am | Bringing the Bench Closer to the Bedside: Advanced in-vitro Validation Models to Study Mechanisms Driving Intestinal Fibrosis

Britta Siegmund
Director Medical Center for Gastroenterology, Infectiology & Rheumatology
Charité Universitätsmedizin Berlin

Pre-Conference Seminar Day

1:00 pm | Examining the Process of Creeping Fat in Humans

Bryan Fuchs
Research Therapeutic Area Head - Gastroenterology & Hepatology
Ferring Pharmaceuticals

Pre-Conference Seminar Day

5:00 pm | Panel Discussion: Clinical Trial Endpoint Development: Establishing a Pathway for Approving Anti-Stricture Therapies in IBD to Drive Clinical Progress

2:30 pm | Similarities & Differences Between Intestinal Fibrosis & Other Fibrotic Diseases

Cara Williams
Vice President
Pfizer

Day One

Tuesday, November 2, 2021

5:00 pm | Chair’s Closing Remarks

8:25 am | Chair’s Opening Remarks

Carmel Nanthakumar
Clinical Development Director
GSK

Day One

Tuesday, November 2, 2021

10:30 am | What is the Next Step in Validating Target Engagement? Identifying Innovative & Non-Invasive Biomarkers of Fibrosis to Enable Diagnosis & Monitor Efficacy

Craig Conoscenti
Executive Director/ Therapeutic Area Head Respiratory ILD Clinical Development & Medical Affairs
Boehringer Ingelheim

Danny Jonigk
Professor
Hannover Medical School

Day Two

Wednesday, November 3, 2021

8:30 am | Investigating COVID-19 Induced Fibrosis to Highlight Novel Mechanistic Pathways

David Lagares
Assistant Professor Of Medicine
Harvard Medical School

Dean Welsch
Chief Scientific Officer
ImmunoMet Therapeutics

Day Two

Wednesday, November 3, 2021

4:15 pm | Targeting Metabolic Remodeling in Fibrosis with IM145

Deborah Nguyen
Vice President, Head of GI / Inflammation Drug Discovery Unit
Takeda

Day Two

Wednesday, November 3, 2021

5:15 pm | Chair’s Closing Remarks

7:55 am | Chair’s Opening Remarks

Elias Papatheodorou
Chief Executive Officer
Genkyotex

Day Two

Wednesday, November 3, 2021

4:45 pm | From Early Research to Late Development in Antifibrotic Drugs: Mind the Translational Gap

Elizabeth Redente
Associate Professor
National Jewish Health

Day One

Tuesday, November 2, 2021

4:00 pm | Establishing Robust and Repeatable Small Animal Models That are More Reflective of the Pathophysiology of Fibrosis

Eric White
Senior Clinical Program Lead, ILD
Boehringer Ingelheim

Day One

Tuesday, November 2, 2021

1:30 pm | The Open Source Imaging Consortium (OSIC) – A Collaborative Model for Imaging Biomarker Discovery in Interstitial Lung Diseases

Day Two

Wednesday, November 3, 2021

2:00 pm | Panel Discussion: What Does a Creative Clinical Trial Design Look Like & What are the Barriers?

Florian Rieder
Director, Head of Co-Section & Inflammatory Bowel Diseases Specialist
Cleveland Clinic

Pre-Conference Seminar Day

5:30 pm | Chair’s Closing Remarks

5:00 pm | Panel Discussion: Clinical Trial Endpoint Development: Establishing a Pathway for Approving Anti-Stricture Therapies in IBD to Drive Clinical Progress

10:00 am | Preclinical Discovery, Validation & Clinical Development Programs in IBD Associated Fibrosis

9:55 am | Chair’s Opening Remarks

Frank Anania
Deputy Director for the Division of Hepatology & Nutrition (DHN)
FDA

Henrik Landgren
Associate Scientific Director, Precision Medicine, Immunology & Fibrosis
AbbVie

Day One

Tuesday, November 2, 2021

11:30 am | Assessing Available Biomarkers for Predicting Patient Stage & to Inform Clinical Stratification

Joe Arron
Vice President & Senior Fellow, Immunology Discovery
Genentech

Day Two

Wednesday, November 3, 2021

8:00 am | Reprogramming Dysfunctional Epithelial Cells to Promote Tissue Repair in Fibrotic Disorders

Joe Garcia
Founder & Chief Executive Officer
Aqualung Therapeutics

Day Two

Wednesday, November 3, 2021

1:00 pm | Biologic Targeting of eNAMPT to DAMPen Organ Inflammation & Attenuate Fibrosis

Joe Sarret
Chief Executive Officer
CohBar

Day Two

Wednesday, November 3, 2021

1:30 pm | Employing Breakthrough Antifibrotic Therapeutics Across Multiple Organs to Illuminate Pipeline Development

Johann Gudjonsson
Arthur C. Curtis Professor of Skin Molecular Immunology
University of Michigan

Kristoffer Ostridge
Head of Respiratory Clinical Knowledge & Imaging
AstraZeneca

Day One

Tuesday, November 2, 2021

11:00 am | Embracing Alternative Imaging Methodologies: Non-Invasive Imaging to Monitor Detection & Progression of Fibrosis

KT Park
Principal Medical Director in IBD
Genentech

Pre-Conference Seminar Day

5:00 pm | Panel Discussion: Clinical Trial Endpoint Development: Establishing a Pathway for Approving Anti-Stricture Therapies in IBD to Drive Clinical Progress

4:30 pm | Addressing Unmet Medical Needs in Intestinal Strictures: Developing a Path for Approved Therapies in Fibrostenotic Crohn’s Disease

Liat Hayardeny
Chief Scientific Officer
Galmed Pharmaceuticals

Day Two

Wednesday, November 3, 2021

3:15 pm | Aramchol – Lessons Learned & Optimization Towards Registrational Part of Phase 3 Clinical Study

Lisa Schopf
Senior Director, Project Lead
Pfizer

Day One

Tuesday, November 2, 2021

3:30 pm | Overcoming the Lack of Relevant Predictive Models: What Does the Industry Need to Define What ‘Good’ Looks Like?

Majd Mouded
Executive Director
Novartis Institutes for BioMedical Research

Day Two

Wednesday, November 3, 2021

2:00 pm | Panel Discussion: What Does a Creative Clinical Trial Design Look Like & What are the Barriers?

Meera Ramanujam
Director, Disease Insights Accelerator & Biomarker Discovery
Boehringer Ingelheim

Pre-Conference Seminar Day

10:30 am | Targeting IL-36R Pathway In IBD- Opening New Doors for Novel Therapies

Nobuhiko Kamada
Associate Professor of Internal Medicine
University of Michigan

Pre-Conference Seminar Day

12:30 pm | Understanding the Role of the Gut Microbiome in Intestinal Fibrosis

Orit Rozenblatt- Rosen
Head, Cellular & Tissue Genomics, Executive Director
Genentech

Day One

Tuesday, November 2, 2021

8:30 am | Generated Single-Cell and Spatial Atlases of Autopsy Tissue Samples from Donors who Died of COVID-19

Paul Noble
Chair
Department of Medicine, Cedars Sinai Medical Center

Day Two

Wednesday, November 3, 2021

11:00 am | New Insights into Mechanisms of Alveolar Type 2 Cell Renewal in Pulmonary Fibrosis

Peter Higgins
Director of Inflammatory Bowel Disease (IBD) Program
University of Michigan

Pre-Conference Seminar Day

5:00 pm | Panel Discussion: Clinical Trial Endpoint Development: Establishing a Pathway for Approving Anti-Stricture Therapies in IBD to Drive Clinical Progress

3:00 pm | Analyzing Developments in Non-Invasive Biomarkers to Predict or Detect Intestinal Fibrosis

Peter Schafer
Vice President, Translational Medicine
Bristol Myers Squibb

Day One

Tuesday, November 2, 2021

1:00 pm | Update from the Prognostic Lung Fibrosis Consortium (PROLIFIC)

Pnina Fishman
Chief Executive Officer & Chief Scientific Officer
Can Fite BioPharma

Day Two

Wednesday, November 3, 2021

3:45 pm | Driving Innovation to Shape Future Pipelines: Latest Updates on Clinical Trial Data

Richard Torstenson
Senior Regulatory Affairs Director
AstraZeneca

Day One

Tuesday, November 2, 2021

2:00 pm | Exploring Regulatory Challenges in Demonstrating Safety & Efficacy in Combination Therapies

Robert Lafyatis
Professor
University of Pittsburgh

Rohit Batta
Chief Medical Officer
Vicore Pharma

Day One

Tuesday, November 2, 2021

4:30 pm | A Journey Through the Models of Organ Fibrosis From the Simple to the State of the Art & Optimizing Preclinical Models for Novel Antifibrotic Targets

Samir Ounzain
Scientific Co- Founder & Chief Executive Officer
HAYA Therapeutics

Day Two

Wednesday, November 3, 2021

9:00 am | What is the Next Drug Target for Treating Fibrosis? Rethinking Approaches to Target Identification

Tamas Schweighoffer
Chief Scientific Officer
Alentis Therapeutics

Day One

Tuesday, November 2, 2021

9:00 am | Assessing Contributing Molecular Mechanisms of Fibrosis & Identifying Common Threads Across Organs